Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference

Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference
Solid Biosciences targets delivery challenge

Solid Biosciences announced that Chief Medical Officer Gabriel Brooks, M.D., will present at FierceBiotechWeek in Boston on Wednesday, May 13.

Brooks will address one of genetic medicine’s pressing challenges: achieving precise delivery of therapies where they are most needed. The session, scheduled from 10:10 to 10:35 am, will focus on innovative solutions and strategies being developed by the company. Brooks’s remarks are expected to draw attention from both industry peers and researchers seeking breakthroughs in targeted gene delivery.

Details about the specific methods or data to be shared have not been disclosed.

Solid Biosciences recently presented new targeting strategies in precision gene therapy at a major symposium, highlighting its work in the field here. The company has also advanced its SGT-212 gene therapy for Friedreich ataxia into human trials, targeting neuromuscular and cardiac symptoms here. These developments mark a continued focus on improving targeted gene delivery.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.